Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
In patients with at least moderate persistent allergic asthma controlled with inhaled
steroids, omalizumab(administered per US product label), when compared to placebo, will
provide the participants with significantly improved tolerability of specific allergen
immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).